Baird lowered the firm’s price target on Contineum (CTNM) to $16 from $32 and keeps an Outperform rating on the shares. The firm said its Phase 2 results in relapsing-remitting MS is on track for the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM: